Trial reportJournal of veterinary internal medicine2016
Posaconazole Pharmacokinetics in Healthy Cats after Oral and Intravenous Administration.
Trial report in Journal of veterinary internal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 28 citations in OpenAlex.
- Invasive fungal infections and oomycoses in cats 2. Antifungal therapy.Journal of feline medicine and surgery · 2024Review
- Antifungal susceptibility profile of yeasts isolated from the oral cavity of cats.Veterinary medicine and science · 2023Article
- Pharmacokinetics of isavuconazole in healthy cats after oral and intravenous administration.Journal of veterinary internal medicine · 2022Article
- Complete clinical response to combined antifungal therapy in two cats with invasive fungal rhinosinusitis caused by crypticMedical mycology case reports · 2021Article
- Disseminated invasive aspergillosis caused by Aspergillus felis in a cat.Journal of veterinary internal medicine · 2021Article
- An atypical cause of sporotrichosis in a cat.Medical mycology case reports · 2019Article
- Clinical utility of fungal culture and antifungal susceptibility in cats and dogs with histoplasmosis.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPosaconazole is the most active available azole antifungal drug, but absorption and pharmacokinetics are not available to guide dosing regimens in cats.
objectiveTo determine the pharmacokinetics of posaconazole in cats given an IV solution and PO suspension. ANIMALS: Six healthy, adult research cats.
methodsAfter a 12-hour fast, each cat received 15 mg/kg of posaconazole PO suspension with food. Four cats also received 3 mg/kg IV posaconazole after a 7-day washout period. Plasma was collected at predetermined intervals for analysis using high-pressure liquid chromatography (HPLC). Concentration data were analyzed using a 2-compartment pharmacokinetic analysis for IV administration data and a 1-compartment analysis with first-order input for PO administration data using Phoenix
resultsAfter IV dosing, volume of distribution (V CONCLUSION AND CLINICAL IMPORTANCE: Despite low PO absorption, these data allow for simulation of PO dosage regimens that could be explored in clinical studies. Two regimens can be considered to maintain targeted trough concentrations of 0.5-0.7 μg/mL as extrapolated from studies in humans: (1) 30 mg/kg PO loading dose followed by 15 mg/kg q48h, or (2) 15 mg/kg PO loading dose followed by 7.5 mg/kg q24h.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.